Soleno Therapeutics Files 8-K

Ticker: SLNO · Form: 8-K · Filed: 2025-08-06T00:00:00.000Z

Sentiment: neutral

Topics: corporate-filing, 8-K, financial-reporting

Related Tickers: SLNO

TL;DR

SOLENO THERAPEUTICS (SLNO) filed an 8-K on 8/6/25, confirming fiscal year end and corporate details.

AI Summary

On August 6, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing indicates the company's fiscal year ends on December 31st. Soleno Therapeutics, formerly Capnia, Inc., is incorporated in Delaware and its principal executive offices are located in Redwood City, California.

Why It Matters

This 8-K filing provides standard corporate information and updates regarding Soleno Therapeutics, Inc.'s operational and financial reporting status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K with standard corporate information and does not appear to contain material non-public information that would immediately impact stock price.

Key Numbers

001-36593 — SEC File Number (Identifies the company's filing with the SEC.)
77-0523891 — IRS Employer Identification Number (Company's tax identification number.)

Key Players & Entities

SOLENO THERAPEUTICS, INC. (company) — Registrant
Capnia, Inc. (company) — Former company name
August 6, 2025 (date) — Date of report
Delaware (jurisdiction) — State of incorporation
Redwood City, CA (location) — Principal executive offices
1231 (date) — Fiscal year end

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting standard corporate information and the date of the earliest event reported.

When was the report filed and what is the earliest event date?

The report was filed on August 6, 2025, and the earliest event reported is also August 6, 2025.

What is Soleno Therapeutics, Inc.'s fiscal year end?

Soleno Therapeutics, Inc.'s fiscal year ends on December 31st.

What was Soleno Therapeutics, Inc. formerly known as?

Soleno Therapeutics, Inc. was formerly known as Capnia, Inc.

Where are Soleno Therapeutics, Inc.'s principal executive offices located?

Soleno Therapeutics, Inc.'s principal executive offices are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.

From the Filing

0001193125-25-174458.txt : 20250806 0001193125-25-174458.hdr.sgml : 20250806 20250806161023 ACCESSION NUMBER: 0001193125-25-174458 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 251189638 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d88313d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-08-06 2025-08-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Parkway , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbols   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       ITEM 2.02 Results of Operations and Financial Conditions On August 6, 2025, Soleno Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. This information is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#82